All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
In March 2022, Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne University, Paris, FR, held a live virtual Journal Club, organized by the International Academy for Clinical Hematology (IACH), joined by Naveen Pemmaraju, MD Anderson Cancer Center, Houston, US, and Ibrahim Yakoub-Agha, CHU de Lille, Lille, FR.1 The panel discussed the results of the recently published phase II REFINE trial (NCT03222609)2 on the efficacy and safety of the addition of navitoclax to ruxolitinib in patients with persistent or progressive myelofibrosis. The MPN Hub is pleased to summarize highlights from the event, below.
Overall, the panel emphasized that despite the relatively low number of patients, the preliminary results published in the study are encouraging. Combination therapy of navitoclax with ruxolitinib may provide a novel treatment approach for patients with suboptimal response to Janus kinase (JAK) inhibitors. The study can pave the way for further investigation on combination therapies for patients with persistent or progressive myelofibrosis.
Below, we provide a visual abstract summarizing key efficacy and safety results from the REFINE trial, which were recently published in the Journal of Clinical Oncology.2
To download this visual abstract, click below.Download here
Novel agents to treat MF with suboptimal response to ruxolitinib: Combining ruxolitinib with navitoclax or KRT-232
Janus kinase (JAK)–signal transducer and activator of transcription (STAT) pathway dysregulation is central to the pathogenesis of...
Can navitoclax plus ruxolitinib induce clinically relevant responses in patients with myelofibrosis?
The MPN Hub were pleased to speak to Jacqueline S. Garcia, Dana-Farber Cancer Institute, Boston, US, during the 61st American Society of Hematology...
Subscribe to get the best content related to MPN delivered to your inbox